#China #NASDAQ #Beijing #LakeShore Biopharma #Delisting

LakeShore Biopharma Faces Nasdaq Delisting

LakeShore Biopharma Co., Ltd, a notable player in the biopharmaceutical industry focusing on innovative vaccines and therapeutic biologics, recently announced a significant development that could affect its future operations. On September 11, 2025, Nasdaq communicated a determination letter to LakeShore Biopharma, stating that the company is non-compliant with the exchange's Listing Rule 5550(a)(2), commonly known as the Bid Price Rule. This rule necessitates that the company's ordinary shares maintain a minimum closing bid price of $1.00 per share.

The letter highlights that LakeShore's stock has remained below this crucial threshold for 30 consecutive business days. This situation places the company in a precarious position, as the letter outlines that they are not eligible for the standard 180-day compliance period to rectify this issue. The underlying reason for this ineligibility stems from a recent event wherein LakeShore executed a 10-for-1 reverse stock split on October 1, 2024. Following such a split, under Nasdaq Listing Rule 5810(c)(3)(A)(iv), companies lose their opportunity for a compliance period.

As a consequence of this ruling, Nasdaq has indicated its intent to delist LakeShore Biopharma from the Nasdaq Capital Market. Unless the company opts to request an appeal, trading of its securities will cease at the start of business on September 22, 2025. A form 25-NSE will then be filed with the Securities and Exchange Commission to deregister the company's securities from Nasdaq. However, the company has until September 18, 2025, to appeal this determination, which would temporarily delay the suspension of its stock pending a decision from the Nasdaq Hearings Panel.

LakeShore Biopharma is now at a crossroads, evaluating its options following this determination. The management team is contemplating whether to pursue an appeal and navigate the challenges ahead that come with compliance and regulatory requirements. It acknowledges the uncertainty surrounding this decision, particularly regarding the potential success of any appeal and the capability to regain compliance with Nasdaq’s listing standards.

Amid this situation, it’s essential to note that this announcement was made in accordance with Nasdaq Listing Rule 5810(b), which mandates immediate disclosure of any receipt of a delisting determination. This prompt communication reflects LakeShore Biopharma's commitment to regulatory transparency.

About LakeShore Biopharma

Previously known as YS Biopharma, LakeShore Biopharma is on the forefront of sustaining advancements in the biopharmaceutical sector. The company offers a wide array of innovative vaccines and therapeutic options targeting infectious diseases and various forms of cancer. Among its key assets is the proprietary PIKA® immunomodulating technology platform, which enables the development of a new generation of preventive and therapeutic biologics aimed at addressing urgent health challenges such as Rabies, Hepatitis B, and Influenza.

Operational in key regions including China, Singapore, and the Philippines, LakeShore is led by a diverse management team with extensive expertise in biopharmaceutical development and commercialization. As the company charts its future amidst this delisting challenge, stakeholders and investors remain watchful of the unfolding events. Detailed information about LakeShore Biopharma can be accessed through their investor relations portal at LakeShore's Investor Site.

Looking Ahead

The current challenge faced by LakeShore Biopharma underscores the volatility inherent in the biotech and pharmaceutical sectors. Stakeholders will need to consider the implications of such delistings, not only on stock performance but also on the company's ability to raise capital and sustain its research and development efforts. The coming weeks will be critical as the company deliberates its next steps and seeks to navigate this turbulent period. Investors and analysts alike will be closely monitoring the situation for clues about LakeShore's long-term viability in a competitive biopharmaceutical landscape.